10.3760/cma.j.issn.1673-422X.2015.04.019

Abstract

Sheng-Neng-Quan-；Yang-Yi-；Wang-Zhi-Gang. 10.3760/cma.j.issn.1673-422X.2015.04.019[J]. Journal of International Oncology, 2015, 42(4): 309-312.

［1］ Oberndorfer S. Karzinoide tumoren des dunndarms［J］. Frankf Z Pathol, 1907, 1: 426432. ［2］ Modlin IM, Lye KD, Kidd M. A 5decade annlysis of 13,715 carcinoid tumors［J］. Cancer, 2003, 97(4): 934959. ［3］ Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors［J］. Endocrinol Metab Clin North Am, 2011, 40(1): 118. ［4］ Ito T, Igarashi H, Nakamura K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis［J］. J Gastroenterol, 2015, 50(1): 5864. ［5］ Tsai HJ, Wu CC, Tsai CR, et al. The epidemiology of neuroendocrine tumors in Taiwan: a nationwide cancer registrybased study［J］. PLoS One, 2013, 8(4): e62487. ［6］ Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems［J］. Pancreas, 2010, 39(6): 707712. ［7］ Pape UF, Berndt U, MüllerNordhorn J, et al. Prognostic factors of longterm outcome in gastroenteropancreatic neuroendocrine tumours［J］. Endocr Relat Cancer, 2008,15(4): 10831097. ［8］ Lawrence B, Gustafsson BI, Kidd M, et al. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors［J］. Endocrinol Metab Clin North Am, 2011, 40(1): 111314. ［9］ Dronamraju SS, Joypaul VB. Management of gastrointestinal carcinoid tumours  10 years experience at a district general hospital［J］. J Gastrointest Oncol, 2012, 3(2): 120129. ［10］ Gnanaseqaran G, O′Doherty MJ. Imaging neuroendocrine tumours with radionuclide techniques［J］. Minerva Endocrinol, 2008, 33(2):105126. ［11］中国胃肠胰神经内分泌肿瘤病理专家组.中国胃肠胰神经内分泌肿瘤病理学诊断共识［J］. 中华病理学杂志, 2011, 40(4): 257262. ［12］ Knigge U, Hansen CP. Surgery for GEPNETs［J］. Best Pract Res Clin Gastroenterol, 2012, 26(6): 819831. ［13］ Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study［J］. Endocr Relat Cancer, 2009, 16(3): 885894. ［14］ Scherübl H, Jensen RT, Cadiot G, et al. Management of early gastrointestinal neuroendocrine neoplasms［J］. World J Gastrointest Endosc, 2011, 3(7): 133139. ［15］ Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors［J］. N Engl J Med, 2011, 364(6): 501513. ［16］ Ahn HK, Choi JY, Kim KM, et al. Phase Ⅱ study of pazopanib monotherapy in mentastatic gastroenteropancreatic neuroendocrine tumours［J］. Br J Cancer, 2013, 109(6): 14141419. ［17］ Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors［J］. N Engl J Med, 2011, 364(6): 514523. ［18］ Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors［J］. World J Gastroenterol, 2010, 16(24): 29632970. ［19］ Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors［J］. N Engl J Med, 2014, 371(3): 224233. ［20］ Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: welldifferentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum［J］. Pancreas, 2010, 39(6): 753766. ［21］ Castao JP, Sundin A, Maecke HR, et al. Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges［J］. Cancer Metastasis Rev, 2014, 33(1): 353359. ［22］ Platanias LC. Mechanisms of typeⅠ and typeⅡinterferonmediated signaling［J］. Nat Rev Immunol, 2005, 5(5): 375386. ［23］ berg K, Knigge U, Kwekkeboom D, et al. Neuroendocrine gastroenteropancreatic tumors: ESMO Clinical Practice for diagnosis, treatment and followup［J］. Ann Oncol, 2012, 23 Suppl 7: vii124130. ［24］ Basu B, Sirohi B, Corrie P. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin［J］. Endocr Relat Cancer, 2010, 17(1): R7590. ［25］ Casciano R, Wang X, Stern L, et al. International practice patterns and resource utilization in the treatment of neuroendocrine tumors［J］. Pancreas, 2013, 42(2): 339347. ［26］ Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)［J］. Gut, 2012, 61(1): 632.

[1]	Wang Jun, Jia Xiuhong.TGF-β/Smad signal pathway and acute leukemia[J]. Journal of International Oncology, 2023, 50(8): 498-502.
[2]	Huang Rui, Zhang Yunqing.Clinical efficacy of anlotinib monotherapy in second-line treatment of extensive stage small cell lung cancer with poor PS score[J]. Journal of International Oncology, 2023, 50(12): 705-710.
[3]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang.Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer[J]. Journal of International Oncology, 2022, 49(9): 555-559.
[4]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou.Advances in immunotherapy for recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2022, 49(9): 517-520.
[5]	Xu Hangcheng, Wu Yun, Wang Jiayu.Research progress of breast cancer with low HER2 expression[J]. Journal of International Oncology, 2022, 49(9): 513-516.
[6]	Zhou Xinyu, Jia Xiuhong.Research progress of ferroptosis in the treatment of leukemia[J]. Journal of International Oncology, 2022, 49(12): 759-762.
[7]	Wang Yue, Wu Qiong, Xu Yuan, Gong Wei, Xu Xiaoting.Screening and treatment progression of elderly cervical cancer[J]. Journal of International Oncology, 2022, 49(12): 754-758.
[8]	Zhang Dandan, Yue Hongyun, Zhang Baihong.Adaptive therapy of human cancers: targeting cancer evolution[J]. Journal of International Oncology, 2020, 47(6): 368-371.
[9]	Zhang Baihong, Yue Hongyun.Application of selective CDK4/6 inhibitors in solid cancers therapy[J]. Journal of International Oncology, 2019, 46(6): 350-357.
[10]	Mo Qiuping, Chen Yiding, Wang Xiaochen, . Application of CDK4/6 inhibitors in the treatment of hormone receptorpositive breast cancer[J]. Journal of International Oncology, 2019, 46(10): 617-619.
[11]	Luo Mengchao, Ding Chaofeng, Wu Jian, Zheng Shusen.Treatment progress of intrahepatic cholangiocarcinoma[J]. Journal of International Oncology, 2016, 43(1): 60-63.
[12]	HE Chun-Xiao, SONG Zheng-Bo, ZHANG Yi-Ping.Impact and treatment of chemotherapy-induced anemia on lung cancer patients[J]. Journal of International Oncology, 2013, 40(4): 278-283.
[13]	FU Chun.Application of diffusion-weighted imaging in the diagnosis and treatment of cervical cancer[J]. Journal of International Oncology, 2012, 39(6): 449-452.
[14]	ZHOU Shi-Qiu, LOU Shi-Feng, LUO Yun.Allogeneic stem cell transplantation in multiple myeloma[J]. Journal of International Oncology, 2012, 39(4): 301-304.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles14

Recommended Articles

Metrics

Comments